Gene therapy Archives

VectorBuilder Research and Manufacturing Campus

News and Trends 2 Nov 2022

VectorBuilder to build gene delivery campus after $57M funding

Gene delivery technology company VectorBuilder Inc. has announced the completion of $57 million in funding. The funding, co-led by Legend Capital, will support the construction of VectorBuilder’s new Gene Delivery Research and Manufacturing Campus, and further boost the company’s R&D capabilities and global business presence. VectorBuilder was established in 2014 to commercialize its novel e-commerce […]

November 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Oct 2022

Replay Bio launches HSV gene therapy company to target retinal eye disease

Replay Bio has announced the launch of Eudora, an HSV (herpes simplex virus) gene therapy company targeting genetic retinal diseases. It is the first of Replay’s product companies to leverage its high payload capacity HSV delivery vector, synHSV. Eudora’s co-founders Joe Glorioso, Mark Blumenkranz, David Schaffer, and Vinit Mahajan, are entrepreneurs who have worked in […]

October 31, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 26 Oct 2022

ABL and RD-Biotech to partner on cell and gene therapy manufacturing

French companies ABL and RD-Biotech have signed a strategic partnership to cover cell and gene therapy (C&GT) GMP manufacturing. ABL, is a contract development and manufacturing organization (CDMO) that specializes in the development and manufacturing of solutions for biopharma, including viruses for gene therapies, oncolytic viruses and vaccine candidates. RD-Biotech is a CRO (contract research […]

October 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 24 Oct 2022

Syncona to acquire Applied Genetic Technologies Corporation

Healthcare company Syncona Limited says its newly established portfolio company has agreed to acquire, by a tender offer, all outstanding shares of Applied Genetic Technologies Corporation (AGTC). AGTC is a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an […]

October 24, 2022 - 2 minutesmins - By Jim Cornall

In Depth 20 Oct 2022

Opportunities and challenges for cell and gene therapy investments

Companies in the cell and gene therapy space are struggling to raise investments amid adverse market conditions. However, this could be an opportunity for the strongest companies and investors to shine. After several years of record-breaking investments, funding is hard to come by in the gene and cell therapy space. Part of this trend relates […]

October 20, 2022 - 9 minutesmins - By Jonathan Smith

News and Trends 13 Oct 2022

Xcell Biosciences and aCGT Vector pushing ahead with cell and gene therapies

Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, and aCGT Vector, a point-of-care cell and gene therapy-as-a-service (TaaS) company, are collaborating to improve manufacturing and analytic procedures to develop personalized cell and gene therapies for cancer patients. aCGT Vector will provide its point-of-care, GMP-licensed manufacturing platform to validate Xcellbio’s […]

October 13, 2022 - 2 minutesmins - By Jim Cornall

Anastasiia Slynko biotech investment 744x368 1

In Depth 11 Oct 2022

The biggest private biotech investments in September 2022

The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […]

October 11, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 3 Oct 2022

Alexion, AstraZeneca Rare Disease to acquire genomic medicine company LogicBio Therapeutics

LogicBio Therapeutics, Inc. has entered into a definitive agreement under which Alexion, AstraZeneca Rare Disease (Alexion) will acquire LogicBio. The proposed acquisition brings LogicBio’s technology, experienced rare disease R&D team, and expertise in pre-clinical development to support Alexion’s growth in genomic medicines. Fred Chereau, president and chief executive officer at LogicBio, said: “We are excited […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

More News! 29 Sep 2022

Removing binding sites for an oncogene can slow cancer cell growth, researchers say

Cancer cell growth could be slowed down by removing binding sites for an oncogene, researchers from the University of Helsinki have discovered. They have found a mechanism by which an oncogene commonly activated in cancer patients affects the growth rate of cells. In the future, the findings can help in developing new treatments that could […]

September 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Sep 2022

Promising MND drug slows disease progression

Scientists in the U.K. believe a new genetically-targeted therapy to treat motor neurone disease (MND) could be a turning point for patient care. Results from a phase 3 clinical trial showed significant physical benefits for patients after 12 months. Researchers from the Sheffield Institute for Translational Neuroscience (SITraN) found that patients with a faulty SOD1 […]

September 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 20 Sep 2022

Bioreactor platform launched to support process development for cell and gene therapy

A medical technology company, today announced the launch of a bioreactor platform that supports process development through to commercial manufacturing for the cell and gene therapy (CGT) sector. Terumo Blood and Cell Technologies (Terumo BCT) named its Quantum Flex Cell Expansion System, after identifying the industry’s need for earlier automation to potentially limit additional and […]

September 20, 2022 - 3 minutesmins - By Liza Laws

News and Trends 20 Sep 2022

CGT Catapult begins VR training to help ensure future workforce needs

A first-of-its-kind pilot to provide augmented reality (AR) and virtual reality (VR) training to develop the knowledge and skills needed for a career in advanced therapy medicinal product (ATMP) development has been launched. The training will be done by the Cell and Gene Therapy Catapult (CGT Catapult), in partnership with the University of Sheffield Advanced […]

September 20, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Gene therapy

VectorBuilder to build gene delivery campus after $57M funding

Replay Bio launches HSV gene therapy company to target retinal eye disease

ABL and RD-Biotech to partner on cell and gene therapy manufacturing

Syncona to acquire Applied Genetic Technologies Corporation

Opportunities and challenges for cell and gene therapy investments

Xcell Biosciences and aCGT Vector pushing ahead with cell and gene therapies

The biggest private biotech investments in September 2022

Alexion, AstraZeneca Rare Disease to acquire genomic medicine company LogicBio Therapeutics

Removing binding sites for an oncogene can slow cancer cell growth, researchers say

Promising MND drug slows disease progression

Bioreactor platform launched to support process development for cell and gene therapy

CGT Catapult begins VR training to help ensure future workforce needs

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!